(3R,4S)-3-hydroxy-4-isobutylazetidin-2-one | 156742-12-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (3R,4S)-3-hydroxy-4-isobutylazetidin-2-one
• 英文别名: (3R,4S)-3-hydroxy-4-(2-methylpropyl)azetidin-2-one
• CAS: 156742-12-0
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: CNYWEOKDRLOJIZ-NTSWFWBYSA-N

物化性质

• 沸点：
  320.8±35.0 °C(Predicted)
• 密度：
  1.089±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3R,4S)-3-hydroxy-4-isobutylazetidin-2-one 在 盐酸 作用下， 反应 4.0h， 生成 (2R,3S)-3-amino-2-hydroxy-5-methylhexanoic acid
  参考文献：
  名称：

  N，N-二烷基hydr与烯酮之间的立体选择性[2 + 2]环加成反应的研究。

  摘要：

  手性，非外消旋的N，N-二烷基alkyl唑酮1和官能化的烯酮之间的类Staudinger样环加成反应构成了β-内酰胺环立体选择性构建的有效方法。强调了二烷基氨基辅助结构的微调潜力，释放游离氮杂环丁酮的高产脱保护方法的可用性以及作为N-二烷基氨基亚胺的high的高热稳定性和化学稳定性，是其关键要素。该策略的成功。关于通用性，这最后一个方面特别重要：甚至来自易于烯化的醛或甲醛的也反应生成相应的具有高化学和立体化学收率的环加合物。β-氨基-α-羟酸（2R，3S）-苯基异丝氨酸（42）和（2R，作为该程序的合成效用的说明性实例，完成了3S）-去甲他汀（45）的制备。通过从头算的方法研究了g系列助剂的环加成模型系统。收集到的结果通过两性离子中间体支持了两步机理，并根据the的Re面的优选向外环加成解释了观察到的绝对和相对立体化学。

  DOI：

  10.1002/chem.200400452
• 作为产物：
  描述：

  iso-propyl (2R,3S)-3-amino-2-hydroxy-5-methylhexanoate 在 乙醇 、 叔丁基氯化镁 、 三乙胺 作用下， 以 various solvent(s) 为溶剂， 生成 (3R,4S)-3-hydroxy-4-isobutylazetidin-2-one
  参考文献：
  名称：

  Synthesis of the C-13 Side Chain Precursors of the 9-Dihydrotaxane Analogue ABT-271

  摘要：

  [GRAPHICS]N-Boc-L-Leucinol was converted to two C-13 side chain precursors of the 9-dihydrotaxane analogue ABT-271. The trans-oxazolidine acid 4 and the cis-Boc-lactam 2b were prepared in 44% and 40% overall yield, respectively, and with excellent (>98%) stereochemical purity.

  DOI：

  10.1021/ol006508o

文献信息

• Synthesis and Biological Evaluation of C-3'-Modified Analogs of 9(R)-Dihydrotaxol
  作者：Leping Li、Sheela A. Thomas、Larry L. Klein、Clinton M. Yeung、Clarence J. Maring、David J. Grampovnik、Paul A. Lartey、Jacob J. Plattner

  DOI：10.1021/jm00043a005

  日期：1994.8

  Taxol (1) is considered a most exciting new drug in cancer chemotherapy. The promising antitumor activity of 9(R)-dihydrotaxol (3) encouraged us to further explore the structure-activity relationship of this new member of the taxane family. Studies indicated that the C-13 side chain of taxol is indispensable for antitumor activity and that the natural substitution pattern of a 2'(R)-hydroxy and a 3'(S)-acylamino

  紫杉醇（1）被认为是癌症化疗中最令人兴奋的新药。9（R）-二氢紫杉醇（3）的有希望的抗肿瘤活性鼓励我们进一步探索紫杉烷家族这个新成员的结构-活性关系。研究表明，紫杉醇的C-13侧链对于抗肿瘤活性是必不可少的，并且2'（R）-羟基和3'（S）-酰氨基的天然取代方式可能是最佳的。然而，关于3'-苯环对活性的影响了解的很少。描述了在C-3'位置修饰的3的类似物的合成和生物学评估。这项研究表明3'-苯环不是活性所必需的，并鉴定了几种在体外和体内活性均与紫杉醇相同或更高的化合物。
• PYRIDINE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP3150581A1

  公开（公告）日：2017-04-05

  The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

  本发明要解决的问题是提供一种适用于药物组合物的化合物，特别是一种用于治疗夜尿症的药物组合物。 本发明者假定，抑制胎盘亮氨酸氨肽酶（P-LAP）（即裂解 AVP 的氨肽酶）的夜间活性将维持和/或增加内源性 AVP 水平，从而增强抗利尿作用，这将有助于减少夜间排尿次数，并对抑制 P-LAP 的化合物进行了广泛研究。 结果，本发明人发现(2R)-3-氨基-2-[4-（取代的吡啶）-2-基]甲基}-2-羟基丙酸衍生物具有极佳的 P-LAP 抑制活性。本发明者评估了水负荷大鼠的抗利尿作用，发现这些化合物通过抑制 P-LAP 增加了内源性 AVP 水平，从而减少了尿量。因此，本发明提供的化合物有望用作基于 P-LAP 抑制作用的夜尿症治疗剂。
• Pyridine derivatives
  申请人：Astellas Pharma Inc.

  公开号：US10005762B2

  公开（公告）日：2018-06-26

  The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically an agent for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-(pyridylmethyl)-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

  本发明要解决的问题是提供一种适用于药物组合物的化合物，特别是一种治疗夜尿症的药物。 本发明者假定，抑制胎盘亮氨酸氨肽酶（P-LAP）（即裂解 AVP 的氨肽酶）的夜间活性将维持和/或增加内源性 AVP 水平，从而增强抗利尿作用，这将有助于减少夜间排尿次数，并对抑制 P-LAP 的化合物进行了广泛研究。结果，本发明人发现(2R)-3-氨基-2-(吡啶基甲基)-2-羟基丙酸衍生物具有极佳的 P-LAP 抑制活性。本发明者评估了水负荷大鼠的抗利尿作用，发现这些化合物通过抑制 P-LAP 增加了内源性 AVP 水平，从而减少了尿量。因此，本发明提供的化合物有望用作基于 P-LAP 抑制作用的夜尿症治疗剂。
• Pyridine derivative
  申请人：Astellas Pharma Inc.

  公开号：US10059720B2

  公开（公告）日：2018-08-28

  The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

  本发明要解决的问题是提供一种适用于药物组合物的化合物，特别是一种用于治疗夜尿症的药物组合物。 本发明者假定，抑制胎盘亮氨酸氨肽酶（P-LAP）（即能裂解 AVP 的氨肽酶）的夜间活性将维持和/或增加内源性 AVP 水平，从而增强抗利尿作用，这将有助于减少夜间排尿次数，并对抑制 P-LAP 的化合物进行了广泛研究。 结果，本发明人发现(2R)-3-氨基-2-[4-（取代的吡啶）-2-基]甲基}-2-羟基丙酸衍生物具有极佳的 P-LAP 抑制活性。本发明者评估了水负荷大鼠的抗利尿作用，发现这些化合物通过抑制 P-LAP 增加了内源性 AVP 水平，从而减少了尿量。因此，本发明提供的化合物有望用作基于 P-LAP 抑制作用的夜尿症治疗剂。
• TW2016/9654
  申请人：——

  公开号：——

  公开（公告）日：——